Agile Therapeutics (AGRX) has provided an announcement.
Agile Therapeutics, Inc. has entered into a merger agreement with Insud Pharma, S.L. and its subsidiary, where Agile will become an indirect wholly-owned subsidiary of Insud. The merger includes provisions for Agile stock and option holders to receive cash compensation, while certain pre-merger conditions involve agreements with Corium Innovations, Inc. and the cancellation of outstanding warrants. The deal, approved by Agile’s board, is subject to customary closing conditions including stockholder approval and the absence of legal obstacles. Concurrently, Agile has secured a bridge loan from Insud, secured against its intellectual property.
See more insights into AGRX stock on TipRanks’ Stock Analysis page.
